Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil

Journal of Investigational Allergology and Clinical Immunology

Volumn 18, Issue 2, 2008, Pages 84-92

  Guimaraes Junqueira De Queiros M ^a,b   Oliveira Silva, D A ^a   Alves, R ^a   Fukuhara Chiba, H ^c   Soares De Amaral, V B ^b   De Almeida, K C ^a   Ynoue, L H ^a   De Oliveira Resende, R ^a   Camargo Sopelete, M ^a   Rodrigues Silva Segundo, G ^a   Ferreira De Sousa Moreira, P ^a   Sung, S J ^d   Taketomi, Ernesto Akio ^a,e  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b Public Health System   (Brazil)

^c Laboratory of Clinical Analysis   (Brazil)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Instituto de Ciencias Biomedicas   (Brazil)

Author keywords

Allergen specific immunotherapy; Der p 1. Der p 2; Dermatophagoides pteronyssinus; IgG1 and IgG4 subclasses; Immunoglobulin (Ig) E antibody

Indexed keywords

DER P 1 ALLERGEN; DER P 2 ALLERGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; MIXED RESPIRATORY BACTERIAL EXTRACT; PLACEBO;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; ATOPY; BLOOD SAMPLING; BRAZIL; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRICK TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URTICARIA; WHEEZING;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BACTERIA; BRAZIL; CHILD; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL;

EID: 45749090475     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wahn U. Immunotherapy in children. Curr Opin Allergy Clin Immunol. 2002;2:557-60.
2. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558-62.
3. Huggins JL, Looney RJ. Allergen immunotherapy. Am Fam Physician. 2004;70:689-96.
4. Platts-Mills TAE, Thomas WR, Aalberse RC, Vervloet D, Chapman MD. Dust mite allergens and asthma: report of a second international workshop. J Allergy Clin Immunol. 1992;89:1046-60.
5. Tovey E. Effect of Voorhorst's work on the current understanding of the role of house dust mites in allergic diseases. J Allergy Clin Immunol. 2004;113:577-80.
6. Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and healthy: a question of allergen specificity and balance. Int Arch Allergy Immunol. 2004;135:73-82.
7. Jutel M, Akdis M, Budak F, Aebisher-Casualta C, Wrzyszcz M, Baser K, Akdis CA. IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205-14.
8. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology: Practice parameters for allergen immunotherapy. J Allergy Clin Immunol. 1996;98:1001-11.
9. Peng Z, Naclerio RM, Norman PS, Adkinson NF Jr. Quantitative IgE and IgG subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol. 1992;9:519-29.
10. Nakagawa T, Kozeki H, Katagiri J, Fujita Y, Yamashita N, Miyamoto T, Skvaril F. Changes of house dust mite-specific IgE, IgG, and IgG subclass antibodies during immunotherapy in patients with perennial rhinitis. Int Arch Allergy Appl Immunol. 1987;82:95-9.
11. Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Skvaril F, Scheiner O, Kraft D. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy. 1990;45:418-26.
12. Matricardi PM, Bjorksten B, Bonini S, Bousquet J, Djukanovic R, Dreborg S, Gereda J, Malling HJ, Popov T, Raz E, Renz H, Wold A.; EAACI Task Force 7. Microbial products in allergy prevention and therapy. Allergy. 2003;58:461-71.
13. Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr UB, Ebner C. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol. 2004;172:6642-8.
14. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA). Allergy. 2002;57:841-55.
15. Sociedade Brasileira de Pneumologia e Tisiologia: III Consenso Brasileiro de Manejo da Asma. J Pneumol. 2002;28:1-28.
16. Pereira EAL, Silva DAO, Cunha-Júnior JP, Almeida KC, Alves R, Sung SJ, Taketomi EA. IgE, IgG1, and IgG4 antibody responses to Blomia tropicalis in atopic patients. Allergy. 2005;60:401-6.
17. Luczynska CM, Arruda LK, Platts-Mills TA, Miller JD, Lopez M, Chapman MD. A two-site monoclonal antibody ELISA for the quantification of the major Dermatophagoides spp. allergens, Der p I and Der f I. J Immunol Methods. 1989;118:227-35.
18. EAACI: Immunotherapy. Position paper. Allergy. 1988;43:1-33
19. Malling HJ, Weeke B. Immunotherapy. Position paper. EAACI. Allergy. 1993;48:7-35.
20. Malling HJ. Methods of skin testing. Position paper. Allergy. 1993;48:55-6.
21. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34: 958-64.
22. Silva DAO, Gervásio AM, Sopelete MC, Arruda-Chaves E, Arruda LK, Chapman MD, Sung SS, Taketomi EA. A sensitive reverse ELISA for the measurement of specific IgE to Der p 2, a major Dermatophagoides pteronyssinus allergen. Ann Allergy Asthma Immunol. 2001;86:545-50.
23. Rodrigues RM, Sopelete MC, Silva DAO, Cunha-Júnior JP, Taketomi EA, Costa-Cruz JM. Strongyloides ratti antigenic components recognized by IgE antibodies in immunoblotting as an additional tool for improving the immunodiagnosis in human strongyloidiasis. Mem Inst Oswaldo Cruz. 2004;99:89-93.
24. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house dust mite immunotherapy study in asthmatic adults. Allergy. 1997;52:853-9.
25. Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy. 1997;52:274-83.
26. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy. 2003;33:1076-82.
27. Pienkowski MM, Norman PS, Lichtenstein LM. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol. 1985;76:729-34.
28. Yeung VP, Gieni RS, Umetsu DT, Dekruyff RH. Heat-Killed Listeria monocitogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol. 1998;161:4146-52.
29. Mastrandrea F, Serio G, Minardi A, Coradduzza G, Rossi N, Scarcia G, Maietta G, Iacobelli A, Lamanna C, Tursi A. IgE responses to Dermatophagoides pteronyssinus native major allergens Der p 1 and Der p 2 during long-term specific immunotherapy. Allergy. 1997;52:1115-9.
30. Taketomi EA, Silva DAO, Sopelete MC, Gervásio AM, Alves R, Sung SJ. Differential IgE reactivity to Der p 1 and Der p 2 allergens of Dermatopahgoides pteronyssinus in mite-sensitized patients. J Investig Allergol Clin Immunol. 2006;16:104-9.
31. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE reactivities to allergenic components in pollen extracts during specific immunotherapy studied with immunoblotting and the Pharmacia CAP System. Allergy. 2002;57:423-30.
32. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol. 1999;29:2026-36.
33. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol. 1998;102:157-64.
34. Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic diseases. Allergy. 1993;48:559-69.
35. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468-75.